Caris Life Sciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Caris Life Sciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 12.7 times by its yearly operating cash. Higher than 87% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $97 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 85% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $98 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-9.3×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 50% of Healthcare companies in United States.
Cash Locked Ratio
$17For every $100 of sales, $17 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $23 tied up three years earlier.
Less money tied up than 65% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$46Sales grew 214% in 3 years; of every extra $100 of sales, $46 became extra profit.
Higher than 68% of Healthcare companies in United States.
Asset Productivity Ratio
+214% / +57%In 3 years sales changed by +214% while total assets changed by +57%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
12.7×Debt due within a year is covered 12.7 times by its yearly operating cash.
Higher than 87% of Healthcare companies in United States.
Cash Cushion Ratio
+4%Cash, after subtracting all debt, equals 4% of its market value (net cash).
Lower than 59% of Healthcare companies in United States.
Tangible Assets Ratio
98%Of every $100 the company owns, $98 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 85% of Healthcare companies in United States.
Tangible Net Worth Ratio
97%Of every $100 of net worth, $97 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 85% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Caris Life Sciences, Inc. owes $0.52 for every $1 it owns. Caris Life Sciences, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
18.9Investors pay $18.9 for every $1 of Caris Life Sciences, Inc.'s yearly profit, lower than 66% of Healthcare companies in United States.
P/B ratio
15.29The share price is 15.29 times Caris Life Sciences, Inc.'s book value per share, higher than 91% of Healthcare companies in United States.
Market cap
$9.0 BThe total market value of all of Caris Life Sciences, Inc.'s shares at today's price (share price × number of shares), larger than 89% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$592 MWhat Caris Life Sciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.09Net worth divided by the number of shares. The share price of $32.00 is 15.3 times this, which is the P/B above.
Return on equity (ROE)
20.1%Caris Life Sciences, Inc. earned 20.1% on its shareholders' money over the last year, higher than 90% of Healthcare companies in United States.
Owes vs Owns
0.52×Caris Life Sciences, Inc. owes $0.52 for every $1 it owns (moderate), higher than 58% of Healthcare companies in United States.
Dividend yield
NoneCaris Life Sciences, Inc. does not currently pay a dividend.
Revenue growth
+97%Revenue rose 97% in the year to Dec 2025, and grew 46% a year on average over 3 years.
Profit growth
LossCaris Life Sciences, Inc. made a loss in each of the last two years.
Profit margin
-8.4%Caris Life Sciences, Inc. lost $8 for every $100 of revenue.
Interest cover
0.8×Caris Life Sciences, Inc.'s operating profit covered its interest costs 0.8 times in the year to Dec 2025.
Cash vs debt
Net cashCaris Life Sciences, Inc. held $371 M more cash than debt (net cash) at Dec 2025.
Questions
What is Caris Life Sciences, Inc.'s P/E ratio?
Investors pay $18.9 for every $1 of Caris Life Sciences, Inc.'s yearly profit, lower than 66% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Caris Life Sciences, Inc.: $9.0 B ÷ $592 M (30 Jun 2026) = 15.3.
What is Caris Life Sciences, Inc.'s return on equity?
Caris Life Sciences, Inc. earned 20.1% on its shareholders' money over the last year, higher than 90% of Healthcare companies in United States.
How much does Caris Life Sciences, Inc. owe compared with what it owns?
Caris Life Sciences, Inc. owes $0.52 for every $1 it owns (moderate), higher than 58% of Healthcare companies in United States.
Does Caris Life Sciences, Inc. pay a dividend?
No. Caris Life Sciences, Inc. does not currently pay a dividend.
Is Caris Life Sciences, Inc.'s revenue growing?
Revenue rose 97% in the year to Dec 2025, and grew 46% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.